Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study

Purpose: To compare the safety and efficacy of intense pulsed light (IPL) followed by meibomian gland expression (MGX), against monotherapy of MGX.

Methods: Patients with moderate to severe meibomian gland dysfunction (MGD) were 1:1 randomized to 4 sessions of intense pulse light + MGX at 2-week intervals, or 4 sessions of Sham + MGX at 2-week intervals. Both patients and examiners were blinded to the allocation. Outcome measures, evaluated at the baseline (BL) and at a follow-up (FU) conducted 4 weeks after the last IPL session, included fluorescein tear breakup time (TBUT) as the primary outcome measure, OSDI (Ocular Surface Disease Index) questionnaire, Eye Dryness Score (EDS, a visual analog scale (VAS)-based questionnaire), Meibomian gland score (MGS, a score of meibum expressibility and quality in 15 glands on the lower eyelid), daily use of artificial tears, and daily use of warm compresses. In addition, during each treatment session, the number of expressible glands was counted in both eyelids, the predominant quality of meibum was estimated in both eyelids, and the level of pain/discomfort due to MGX and IPL was recorded.

Results: TBUT increased from 3.8±0.2 (μ±standard error of mean (SEM)) to 4.5±0.3 seconds in the control arm, and from 4.0±0.2 to 6.0±0.3 in the study arm. The difference between arms was statistically significant (P < .01). Other signs/symptoms which improved in both arms but were greater in the study arm included MGS (P < .001), EDS (P < .01), the number of expressible glands in the lower eyelids (P < .0001) and upper eyelid (P < .0001), the predominant meibum quality in the lower eyelid (P < .0001) and upper eyelid (P < .0001), and the level of pain due to MGX (P < .0001). Outcome measures which improved in both arms with no significant differences between the two were OSDI (P = .9984), and the daily use of artificial tears (P = .8216). Meibography, daily use of warm compresses, and severity of skin rosacea did not show statistically significant changes in either arm. No serious adverse events were observed. There was a slight tendency for more adverse events in the control group (P = 0.06).

Conclusions: The results of this study suggest that, in patients with moderate to severe symptoms, combination therapy of intense pulse light (IPL) and meibomian gland expression (MGX) could be a safe and useful approach for improving signs of dry eye disease (DED) due to meibomian gland dysfunction (MGD). Future studies are needed to elucidate if and how such improvements can be generalized to different severity levels of MGD.

References

1. Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al.. TFOS DEWS II Introduction. Ocul Surf. 2017. Jul;15(3):269–275. doi: 10.1016/j.jtos.2017.05.005 - DOI - PubMed
2. Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al.. TFOS DEWS II Introduction. Ocul Surf. 2017. Jul;15(3):269–275. doi: 10.1016/j.jtos.2017.05.005 - DOI - PubMed
3. Shimazaki J. Definition and diagnostic criteria of dry eye disease: historical overview and future directions. Invest Ophthalmol Vis Sci 2018. Nov 1;59(14):DES7–12. doi: 10.1167/iovs.17-23475 - DOI - PubMed
4. Shimazaki J. Definition and diagnostic criteria of dry eye disease: historical overview and future directions. Invest Ophthalmol Vis Sci 2018. Nov 1;59(14):DES7–12. doi: 10.1167/iovs.17-23475 - DOI - PubMed
5. Stapleton F, Alves M, Bunya V, Jalbert I, Lekhanont K, Malet F, et al.. TFOS DEWS II epidemiology report. Ocul Surf 2017. Jul; 15(3):334–365. doi: 10.1016/j.jtos.2017.05.003 - DOI - PubMed
6. Stapleton F, Alves M, Bunya V, Jalbert I, Lekhanont K, Malet F, et al.. TFOS DEWS II epidemiology report. Ocul Surf 2017. Jul; 15(3):334–365. doi: 10.1016/j.jtos.2017.05.003 - DOI - PubMed
7. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al.. TFOS DEWS II pathophysiology report. Ocul Surf. 2017. Jul;15(3):438–510. doi: 10.1016/j.jtos.2017.05.011 - DOI - PubMed
8. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al.. TFOS DEWS II pathophysiology report. Ocul Surf. 2017. Jul;15(3):438–510. doi: 10.1016/j.jtos.2017.05.011 - DOI - PubMed
9. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al.. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011. Mar 1;52(4):1930–1937. doi: 10.1167/iovs.10-6997b - DOI - PMC - PubMed
10. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al.. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011. Mar 1;52(4):1930–1937. doi: 10.1167/iovs.10-6997b - DOI - PMC - PubMed